ResearcherNorthwestern UniversityNo recent work listed
Bin Zhang
Matched on ORCID iD 0000-0002-6631-7647; OpenAlex author ID A5100392858. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2020: 4 papers · 2021: 1 paper · 2022: none · 2023: 1 paper
Papers 6
- Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC). Last author DOI 10.1038/s41416-023-02344-5↗
- Hypoxia promotes the metastasis of pancreatic cancer through regulating NOX4/KDM5A-mediated histone methylation modification changes in a HIF1A-independent man… Co-author DOI 10.1186/s13148-021-01016-6↗
- Comparative peptidome profiling reveals critical roles for peptides in the pathology of pancreatic cancer. Co-author DOI 10.1016/j.biocel.2020.105687↗
- Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. Co-author DOI 10.1158/1078-0432.ccr-19-2078↗
- Metformin Increases the Chemosensitivity of Pancreatic Cancer Cells to Gemcitabine by Reversing EMT Through Regulation DNA Methylation of miR-663. First author DOI 10.2147/ott.s261570↗
- ALDH1A3 Accelerates Pancreatic Cancer Metastasis by Promoting Glucose Metabolism. Co-author DOI 10.3389/fonc.2020.00915↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Devalingam Mahalingam · 2 shared papers, 2020–2023 · strength 0.26
- Paper Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC). DOI 10.1038/s41416-023-02344-5↗
- Paper Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic … DOI 10.1158/1078-0432.ccr-19-2078↗
- Zhuyin Qian · 2 shared papers, 2020 · strength 0.25
- Yuqing Gu · 2 shared papers, 2020 · strength 0.25
- Xuetian Qian · 2 shared papers, 2020–2021 · strength 0.20
- Hongzhen Li · 2 shared papers, 2020–2021 · strength 0.20
- Shanshan Shen · 2 shared papers, 2020–2021 · strength 0.20
- Shuang Nie · 2 shared papers, 2020–2021 · strength 0.20
- Shu Zhang · 2 shared papers, 2020–2021 · strength 0.20
- Bo Kong · 2 shared papers, 2020–2021 · strength 0.20
- Xiaoping Zou · 2 shared papers, 2020–2021 · strength 0.20
- Sheetal Mehta Kircher · 1 shared paper, 2023 · strength 0.16
- Aparna Kalyan · 1 shared paper, 2023 · strength 0.16
- Al B. Benson · 1 shared paper, 2023 · strength 0.16
- Mary F. Mulcahy · 1 shared paper, 2023 · strength 0.16
- Xingxing Li · 1 shared paper, 2020 · strength 0.11
- Ying Lv · 1 shared paper, 2021 · strength 0.10
- Helmut Friess · 1 shared paper, 2021 · strength 0.10
- Christos K Fountzilas · 1 shared paper, 2020 · strength 0.10
- Helmut Frieß · 1 shared paper, 2020 · strength 0.09
- Lei Wang · 1 shared paper, 2020 · strength 0.09
- Ying Lv · 1 shared paper, 2020 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.